Velneperit

Overview

Velneperit is a pharmaceutical compound that acts as a peripherally acting mu-opioid receptor antagonist (PAMORA). It is primarily used in the management of opioid-induced constipation (OIC), a common side effect of opioid medications. Velneperit works by blocking the action of opioids on the mu-opioid receptors in the gastrointestinal tract without affecting the central nervous system.

Mechanism of Action

Velneperit selectively targets the mu-opioid receptors located in the gastrointestinal tract. By antagonizing these receptors, it mitigates the constipating effects of opioids, which are often prescribed for pain management. Unlike other opioid antagonists, Velneperit does not cross the blood-brain barrier, thus preserving the analgesic effects of opioids.

Clinical Use

Velneperit is indicated for patients who experience constipation as a result of chronic opioid therapy. It is particularly beneficial for individuals who do not respond adequately to traditional laxatives. The drug is administered orally and is typically well-tolerated.

Side Effects

Common side effects of Velneperit include abdominal pain, diarrhea, and flatulence. These effects are generally mild and transient. Serious adverse effects are rare but may include severe gastrointestinal symptoms.

Pharmacokinetics

Velneperit is absorbed in the gastrointestinal tract and undergoes minimal systemic absorption, which limits its action to the periphery. It is metabolized in the liver and excreted primarily in the feces.

Development and Approval

Velneperit was developed as part of a class of drugs aimed at addressing the side effects of opioid therapy. It has been approved for use in several countries and is subject to ongoing research to explore its full potential and safety profile.

Related pages

• Opioid-induced constipation
• Mu-opioid receptor
• Peripherally acting mu-opioid receptor antagonist
• Pain management

Gallery

Chemical structure of Velneperit